How much revenue does Adynxx make?

Adynxx reported $2.22 million in revenue for fiscal year 2018, up 9.8% from $2.02 million in fiscal year 2017. In Q3 2019 revenue was $0.

What companies are similar to Adynxx?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Athersys, Inc. (ATHXQ), Alzex Neuropharma Inc. (TRRI), Sunset Island Group, Inc. (SIGO), GlobeImmune, Inc. (GBIM).

Adynxx, Inc. (ADYX) Stock

About Adynxx, Inc.

Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-c...

At a glance

Adynxx reported revenue of $2.22 million for fiscal year 2018, up 9.8% from fiscal year 2017, and net income of -$8.42 million. In Q3 2019 (the quarter ended September 30, 2019) revenue was $0, down 100.0% from a year before.

Figures from company filings; latest fiscal year ended December 31, 2018.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.